Stanley A. Plotkin ADVAC /10/2010 2:35 PM
|
|
- Katrina Cobb
- 5 years ago
- Views:
Transcription
1 How and dwh Why Vaccines are Made Stanley A. Plotkin ADVAC /10/2010 2:35 PM 1
2 Vaccines 1. History of vaccination 2. The vaccine industry 3. Why vaccines are developed 4. The current problems of vaccinology 2
3 What is a vaccine? An inactivated or attenuated pathogen or a component of a pathogen (nucleic acid, protein) that when administered to the host, stimulates a protective response of the cells in the immune system 3
4 4
5 5
6 Outline of the Development of Human Vaccines (1) Live Attenuated Killed Whole Purified Proteins Organisms or Polysaccharides Smallpox th Century 19 th Century Rabies 1885 Typhoid 1896 Cholera 1896 Plague 1897 BCG 1927 (Tuberculosis) Yellow Fever 1935 Early 20 th Century Pertussis 1926 (Whole Cell) Influenza 1936 Rickettsia 1938 Diphtheria 1923 Tetanus
7 7
8 Outline of the Development of Human Vaccines (1) Live Attenuated Smallpox 1798 Rabies 1885 Killed Whole Organisms 18 th Century 19 th Century Typhoid 1896 Cholera 1896 Plague 1897 Early 20 th Century Purified Proteins or Polysaccharides BCG 1927 (Tuberculosis) Yellow Fever 1935 Pertussis 1926 (Whole Cell) Diphtheria i 1923 Influenza 1936 Tetanus Rickettsia 1938
9 Daniel Elmer Salmon ( ) 9
10 Theobald Smith ( ) 10
11 Outline of the Development of Human Vaccines (1) Live Attenuated Smallpox 1798 Rabies 1885 Killed Whole Organisms 18 th Century 19 th Century Typhoid 1896 Cholera 1896 Plague 1897 Early 20 th Century Purified Proteins or Polysaccharides BCG 1927 (Tuberculosis) Yellow Fever 1935 Pertussis 1926 (Whole Cell) Diphtheria i 1923 Influenza 1936 Tetanus Rickettsia 1938
12 Emil Adolf von Behring Nobel Prize
13 Kitasato Shibasaburo
14 Paul Ehrlich 14
15 Pierre Paul Émile Roux
16 Gaston Ramon,
17 Outline of the Development of Human Vaccines (1) Live Attenuated Smallpox 1798 Rabies 1885 Killed Whole Organisms 18 th Century 19 th Century Typhoid 1896 Cholera 1896 Plague 1897 Early 20 th Century Purified Proteins or Polysaccharides BCG 1927 (Tuberculosis) Yellow Fever 1935 Pertussis 1926 (Whole Cell) Diphtheria i 1923 Influenza 1936 Tetanus Rickettsia 1938
18 Calmette administering oral BCG vaccination 18
19 Outline of the Development of Human Vaccines (1) Live Attenuated Smallpox 1798 Rabies 1885 Killed Whole Organisms 18 th Century 19 th Century Typhoid 1896 Cholera 1896 Plague 1897 Early 20 th Century Purified Proteins or Polysaccharides BCG 1927 (Tuberculosis) Yellow Fever 1935 Pertussis 1926 (Whole Cell) Diphtheria i 1923 Influenza 1936 Tetanus Rickettsia 1938
20 Max Theiler, South African born physician. Nobel Prize
21 Outline of the Development of Human Vaccines (1) Live Attenuated Smallpox 1798 Rabies 1885 Killed Whole Organisms 18 th Century 19 th Century Typhoid 1896 Cholera 1896 Plague 1897 Early 20 th Century Purified Proteins or Polysaccharides BCG 1927 (Tuberculosis) Yellow Fever 1935 Pertussis 1926 (Whole Cell) Diphtheria i 1923 Influenza 1936 Tetanus Rickettsia 1938
22 John Enders, Frederick Robbins, Thomas Weller,
23 Outline of the Development of Live Attenuated Polio (OPV) Measles Mumps Rubella (ca) Adenovirus Typhoid Ty21a Varicella Cholera CVD103 Zoster Human Vaccines (2) Killed Whole Organisms or Subunit Post World War II Influenza Polio (IPV) Rabies (new) Anthrax Japanese encephalitis Hepatitis A Tick-borne encephalitis E. coli (+ CTB) 23
24 Maurice Hilleman
25 Robert Austrian 25
26 Outline of the Development of Human Vaccines (3) Purified Proteins or Polysaccharide Reassortants Post World War II Genetically Engineered Pneumococcus Influenza Hepatitis B recombinant Meningococcus (killed + live) Cholera toxin Hepatitis B Rotavirus (plasma derived) Pertussis toxin Hifl H. influenzae Papillomavirus i Typhoid (Vi) Pertussis (acellular) H. influenzae, pneumo, mening, (protein conjugated) 26
27 Jane Pittman 27
28 Outline of the Development of Human Vaccines (3) Purified Proteins or Polysaccharide Reassortants Post World War II Genetically Engineered Pneumococcus Meningococcus Hepatitis B (plasma derived) Hifl H. influenzae Typhoid (Vi) Influenza (killed + live) Rotavirus Hepatitis B recombinant Cholera toxin Pertussis toxin Papillomavirus i Pertussis (acellular) H. influenzae, pneumo, mening, (protein conjugated) 28
29 John Robbins 29
30 Outline of the Development of Human Vaccines (3) Purified Proteins or Polysaccharide Reassortants Post World War II Genetically Engineered Pneumococcus Meningococcus Hepatitis B (plasma derived) Hifl H. influenzae Typhoid (Vi) Influenza (killed + live) Rotavirus Hepatitis B recombinant Cholera toxin Pertussis toxin Papillomavirus i Pertussis (acellular) H. influenzae, pneumo, mening, (protein conjugated) 30
31 Herbert Boyer 31
32 Stanley Cohen 32
33 Outline of the Development of Human Vaccines (3) Purified Proteins or Polysaccharide Reassortants Post World War II Genetically Engineered Pneumococcus Meningococcus Hepatitis B (plasma derived) Hifl H. influenzae Typhoid (Vi) Influenza (killed + live) Rotavirus Hepatitis B recombinant Cholera toxin Pertussis toxin Papillomavirus i Pertussis (acellular) H. influenzae, pneumo, mening, (protein conjugated) 33
34 Ilya Ilyich Mechnikov Nobel Prize
35 Dr. Jacques Miller 35
36 Dr. Robert Good 36
37 20th Century Impact of Vaccines Vaccine- Preventable Peak Cases % Disease Cases 2006 Reduction Diphtheria i 30,508 0 Measles 763, Mumps 212,932 6,584 Pertussis 265,269 15,632 Polio (acute) 42,033 0 Polio (paralytic) 21,269 0 Rubella 488, Congenital rubella 20,000 1 Smallpox 110,672 0 Tetanus
38 Infectious Diseases in Children, August 2003, p.19, 38
39 Global Immunization , DTP3 coverage global coverage at 82% in rage g % Cove Global African American Eastern Mediterranean European South East Asian Western Pacific 39
40 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low efficacy unacceptable 4) Often used in infants 5) Given once or a few times 6) Manufacturing larger part of cost 7) High regulatory and quality control burden 8) Supposed to be cheap 40
41 The BIG 5 Vaccine Manufacturers GlaxoSmithKline Merck Novartis Pfizer-Wyeth Sanofi Pasteur 41
42 Smaller Market Share or Limited Range: Baxter Crucell-Berna CSL MedImmune-AstraZeneca Serum Institute of India Avant Bioport ID Biomedical Intercell North American Biologicals RIVM Solvay Statens Serum Inst. 42
43 Producers Outside North America and Europe Japanese Local Producers: Biken, Takeda, Kitasato, Katesuken, Japan BCG Chinese Local Producers : Sinovac, Chengdu, Liao Ning, Wuhan, Dalian, Xiamen Indian Local Producers: Panacea, Bharat, Shanta, Biological E., Indian Immunologicals, Zydus Korean Local lproducers: Green Cross, LG Latin American Local Producers: Butantan, Fiocruz, Birmex, Bio-Manguinhos, Finlay Inst. Biofarma [Indonesia] Saovabha [Thailand] Razi [Iran] IVAC, Vabiotech [Viet Nam] Microgen [Russia] 43
44 Trend in Number of Vaccine Originators Worldwide, Davis, MM, et al. Vaccine in press,
45 Vaccines 6,9 B$ = 1,8 % Pharma Vaccines TOTAL Pharma : 380 B$ 45
46 Size of Vaccine Market 1992 $2.2 billion 1995 $5.4 billion 2000 $6.0 billion 2004 $7.9 billion 2006 $10.2 billion 2009 $18.0 billion 2015 $30 billion 46
47 Why is There an Increase in the Vaccine Market? New vaccines give higher profits Hib, Hepatitis B and Pneumococcal vaccines changed the paradigm of a cheap vaccine 47
48 Worldwide Vaccine Market Share (2008) Vaccines Market Share (%) (1) Others 15.0% SA 21.8% (2) Novartis 8.0% Wyeth 12.3% Merck 21.6% (2) GSK 21.2% (1) 15 B Global Market (1) Based on reported FY2008 results and sanofi-aventis internal estimates for Others (2) Includes 50% of Sanofi Pasteur MSD joint venture sales 48
49 Worldwide Vaccine Market Share (Doses) 6.3 Billion Dose Global Market 36B 3.6 sanofi pasteur 14%.9 B 1.2 B.4 B GSK 20% Others 57% Chiron 7% Merck 1% Wyeth 1% Source: WMA 2004, SP Internal Note: SP MSD sales split by origin 49
50 Reasons Why Vaccine Manufacturers Launch a Development Program 1) Market 2) Market 3) Market 50
51 How Market is Determined 1. Epidemiologic data e.g. Pneumococcal conjugate 2. Demand from consumers in developed countries e.g. Lyme Disease, Acellular Pertussis 3. Demand from authorities in developed countries e.g. Mening C 4. Expert opinion e.g. Mumps 5. Guesses, buttressed by precise but inaccurate 51 data. e.g. Hepatitis B
52 Public Health Interest t Development programs for HIV vaccines based more on this than on expectation of profit 52
53 Technical Feasibility Breakthroughs come from academia and government, and now biotech Importance of f proof of concept. An approach is useless unless it can be scaled up. e.g. vectors Mice lie, or at least exaggerate. e.g. DNA 53
54 Intellectual Property A quagmire May block development or sale e.g. Hepatitis B Lyme 54
55 Fit with Other Vaccines Combinations Travel Vaccines Syndrome Coverage e.g. Meningitis 55
56 The Road to Vaccine Development Academic and Biotech 1. Identify the mechanism of natural protection 2. Isolate the antigen(s) responsible for the protection 3. Show in animals that the vaccine protects 4. Find the best formulation of the antigen Industry 5. Increase yield and purity of vaccine 6. Show the safety of the vaccine in animals 7. Produce a lot under GMP 8. Perform Phase 1, 2, 3, 4 clinical trials 56
57 Phases of Vaccine Development Preclinical - Yield, Animal safety and Immunogenicity Phase 1 - Safety and Immunogenicity (10-100) Phase 2 - Dose, Schedule, Safety, Immunogenicity ( ) Phase 3 - Efficacy, Safety (10,000 70,000) Consistency Phase 4 - Safety (100,000 -, 1,000,000) 57
58 Estimates of Clinical Development and Approval Times Mean Time Duration in Months Study Phase Time (mo.) Preclinical NA Phase I 19.5 Phase II 29.3 Phase III 32.9 Registration, Review and Launch 16.0 Total Excluding Preclinical 97.7 (8+ Yrs.) 58
59 Estimates of Transitional and Cumulative Success Probabilities for Vaccines Transition Probability Preclinical to Phase Phase 1 to Phase II 0.72 Phase II to Phase III 0.79 Phase III to Registration 0.71 Registration to Launch 0.96 Cumulative Launch Probability Preclinical to Launch 0.22 Phase I to Launch 0.39 Phase II to Launch 0.64 Phase III to Launch Registration to Launch
60 Trend in Number of Vaccines in Development Worldwide, Davis, MM, et al. Vaccine in press,
61 The Scientific Problems of Vaccinology at the Beginning of the 21 st Century 1. Induction of long-term B cell memory both effector and central 2. Induction of cellular responses equivalent to natural immunity 3. Overcoming poor neonatal antigen processing 4. Overcoming T cell exhaustion in the elderly 5. Better induction of mucosal immunity 6. Specific adjuvants for selective stimulation of Dendritic B, CD4+, CD8+, Tregs, Th1, Th2, Th 61 17
62 Social Problems for the 21 st Century Safety and Acceptance Cost and Availability Sufficient Production 62
63 Safety Issues Less and less tolerance of reactions Higher and higher levels of regulation Fl False issues may be as costly as true issues 63
64 Critical Needs for Vaccinovigilance More epidemiologic studies of background incidence of serious events e.g. Guillain-Barré, myocarditis Phase IV studies including 1 million vaccinees 64
65 Design of Vaccines Technology is useless unless vaccines are accepted: by authorities e.g. Lyme by public HIV? by vaccinee Flumist Antivaccinationism i i Threatens vaccine coverage 65
66 For New Vaccines, Prices Can Only be Higher R&D Costs/ Risks/ Length of Development Cost of Patents Regulatory Requirements / Quality impacts Current estimate t per vaccine: $ million 66
67 Changes in Vaccine Costs for Childhood and Adolescent Immunization, CDC Catalog CDC Catalog TOTAL $33.70 $ $1, $1, $1, $1, Prices as of 10/31/06 Representative series; other choices are possible. Excise tax of $0.75 per dose per disease prevented (e.g., IPV=$0.75, DTaP=$2.25) is included. CDC and catalog includes 3 doses of HPV recommended for females, $288 and $360, respectively. 67
68 68
69 Vaccines for Poor Countries 1. Tiered pricing 2. Local manufacture 3. Donations by rich countries or philanthropists 4. More investment by governments 69
70 Vaccine Supply Limited production facilities Large capital investment needed Need for new factories/producers in developing countries or pharmaceutical alliances 70
71 Conclusions The Vaccine industry is thriving: i interest in vaccines is high and technology is exploding. However, there are insufficient manufacturers doing research; successful development is complicated and expensive; and without the Gates Foundation, the hopes of extending vaccination to all would be limited. 71
72 Vaccinology A combination of: Microbiology Immunology Epidemiology Public Health and Pharmacy 72
73 The impact of vaccination on the health of the world s peoples is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth. Susan and Stanley Plotkin, A Short History of Vaccination, in Vaccines 1 st Edition,
How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin
How and Why Vaccines Are Developed by Industry Stanley A. Plotkin Merieux 2012 1 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low
More informationHow and Why Vaccines are Made. Stanley A. Plotkin
How and Why Vaccines are Made Stanley A. Plotkin Levine 2017 January 23, 2017 Vaccinology A combination of: Microbiology Immunology Epidemiology Public Health and Pharmacy 2 The impact of vaccination on
More informationHistory of Vaccines. Stanley A. Plotkin ADVAC HISTORY /21/ :21 AM
History of Vaccines Stanley A. Plotkin ADVAC HISTORY 2014 5/21/2014 11:21 AM 1 Sources of Information on The History of Vaccines: Short: Medium: Long: Chapter 1 of the book Vaccines, By Plotkin and Plotkin
More informationCHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES
CHAPTER ONE: EXECUTIVE SUMMARY The Global Vaccine Industry o Scope and Methodology o Overview o Pediatric Preventative Vaccines o The Market o Adult Preventative Vaccines o The Market o Total Market o
More informationTable Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines
Table Of Contents Executive Summary THE GLOBAL VACCINES INDUSTRY Scope and Methodology Overview Pediatric Preventative Vaccines THE MARKET Adult Preventative Vaccines THE MARKET TOTAL MARKET ISSUES AND
More informationECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES
ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES 1 Relationship between research funding and burden of disease Source: Global Forum for Health Research Monitoring Financial Flows for Health Research
More informationEconomics of Vaccine Development A Vaccine Manufacturer s Perspective
Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria
More informationStainless-steel vs Single-use: The Vaccines Perspective
Stainless-steel vs Single-use: The Vaccines Perspective CMO-Biomanufacturer Panel Tue 21 April, Noon-1:30pm, Exhibit Hall Daniel C.Vellom, PhD Sr. Director Global Technology Innovation 2015 INTERPHEX 1
More informationThe Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
More informationCopyright regulations Warning
COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright
More information1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References...
1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References... 7 2 General Recommendations on Immunization Timing and Spacing of Vaccines...
More informationTrends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
More informationVaccines and other immunological antimicrobial therapy 1
Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that
More informationAdolescent vaccination strategies
Adolescent vaccination strategies Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases & Molecular Medicine University of Cape Town www.vacfa.uct.ac.za gregory.hussey@uct.ac.za
More informationPublic Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04.
ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many Medical Policy Title: Immunization Coverage Document: ARB0454:04 Administered by: Public Statement: 1.
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationWalter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate Director, Emory Vaccine Center
Could Vaccines be a Possible Model For Pediatric Drug Development? June 13, 2006 Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate
More informationImmunizations for Children and Teens with Suppressed Immune Systems
Immunizations for Children and Teens with Suppressed Immune Systems Your child is starting treatment that will suppress the immune system. This will affect how your child s body responds to routine immunizations
More informationVaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationMedical Coverage Guidelines are subject to change as new information becomes available.
IMMUNIZATIONS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must
More informationDCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014.
DCVMN AND VACCINE SECURITY IN ASEAN REGION ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. Phuket - Thailand Developing Countries Vaccine Manufacturers Network (DCVMN)
More informationDISEASE PREVENTION & ANTIMICROBIAL USE REDUCTION: IMPACT OF VACCINATION
DISEASE PREVENTION & ANTIMICROBIAL USE REDUCTION: IMPACT OF VACCINATION Anwar Hoosen Department of Medical microbiology University of Pretoria & Tswane Academic Division, NHLS 1 VACCINE ACHIEVEMENTS At
More informationImmunization Update & focus on meningococcal vaccine PART 1
Immunization Update & focus on meningococcal vaccine PART 1 Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases University of Cape Town www.vacfa.uct.ac.za Disclosures Received
More informationTABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationThe Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
More information9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in
More informationVaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
More informationProspective Models of Vaccine Security Collaborations in Research and Development
Prospective Models of Vaccine Security Collaborations in Research and Development Georges Thiry, PhD IVI (International Vaccine Institute) Phuket, Oct 01, 2014 Content R&D Examples of collaborations from
More informationVACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the
More informationSelected vaccine introduction status into routine immunization
Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF
More informationAnnex 1. WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine
WHO related to the manufacture and quality control of biological substances used in medicine WHO are intended to provide guidance to those responsible for the production of biological substances as well
More informationRequirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination.
Requirements for new trials to examine offtarget effects of vaccination Workshop on: Off-target (heterologous/non-specific) effects of vaccination Les Pensieres Jun 8-10, 2015 PEM Fine London School of
More informationPreventative Vaccines. Vaccines for Special Populations. Vaccinations for Adults: An Update. Vaccines Generally Available in the U.S.
Vaccinations for Adults: An Update Preventative Vaccines Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted Lisa G. Winston, MD University of California,
More informationSanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines
Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 Vaccines: the single most effective medical intervention 2 Vaccines save lives Millions of cases
More informationVACCINES TRIUMPHS AND TRIBULATIONS. William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine
VACCINES TRIUMPHS AND TRIBULATIONS William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine Never in the history of human progress has a better and cheaper
More informationCreating VaCCines, ProteCting Life
Creating VaCCines, ProteCting Life PreVenting Disease through VaCCination a Constant BattLe Immunization has been a great public health success story. The lives of millions of children have been saved,
More informationResearch: Sanofi Pasteur, Medimrnune (AstraZeneca), Pfizer, Diassess, Novavax, Merck, GSK, Regeneron, Janssen, Novartis
Joseph Domachowske MD, FAAP Professor of Pediatrics Professor of Microbiology and Immunology SUNY Upstate Medical University Syracuse, NY Consultant: Sanofi Pasteur, Medimmune Research: Sanofi Pasteur,
More informationImmunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR
Immunizations June 5, 2015 Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Disclosures None Goals Understand basic public health impact of immunization Recognize types
More informationOverall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
More informationRole of Partnerships in Developing Innovative Vaccines: Brazil
Role of Partnerships in Developing Innovative Vaccines: Brazil SAGE Meeting, October 2010 Reinaldo Guimarães, M.D, MSc. Secretary of Science, Technology and Strategic Inputs Ministry of Health of Brazil
More informationVaccination and Immunity
Vaccination and Immunity Eric A. Utt, PhD Director, Worldwide Science Policy Pfizer Inc California Immunization Coalition Summit 2012 Completing the Circle: Ensuring Adult & Adolescent Vaccination for
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationVaccines Vaccines elicit immune responses These responses: prevent infectious diseases (ie. prophylaxis)
Vaccines What is a Vaccine? How do Vaccines work? The economics of Vaccines? Do Vaccines prevent disease? Where are new Vaccines needed? What is hot in vaccine development? Vaccines Vaccines elicit immune
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationTHE KEATS GROUP PRACTICE REGISTRATION FORM PLEASE COMPLETE IN BLOCK CAPITALS PERSONAL BACKGROUND INFORMATION
Registration checked by: Date: 11 & Under THE KEATS GROUP PRACTICE REGISTRATION FORM PLEASE COMPLETE IN BLOCK CAPITALS PERSONAL BACKGROUND INFORMATION Male Female Has your child ever been treated at this
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationFamily and Travel Vaccinations
Family and Travel Vaccinations We offer the full range of baby, child and family vaccinations. We are able to tailor schedules to your child s needs or international schedule. We have a suggested vaccination
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationVaccination-Strategies
Vaccination-Strategies Active immunity produced by vaccine Immunity and immunologic memory similar to natural infection but without risk of disease. General Rule: The more similar a vaccine is to the disease-causing
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk
More informationCPT 2016 Code Changes
CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer
More informationHistory and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
More informationImmunization (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Immunization (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1 Realize the significance
More information«20 Years of succesful Hepatitis A vaccines and Future perspectives» Hugues H Bogaerts MD FFPM Global Vaccine Consultant
«20 Years of succesful Hepatitis A vaccines and Future perspectives» Hugues H Bogaerts MD FFPM Global Vaccine Consultant EASL,St Petersburg June, 2012 Vaccine developed Twenty-seven diseases are now vaccine
More informationTechnology Transfer from the Perspective of IFPMA vaccine members
Technology Transfer from the Perspective of IFPMA vaccine members WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Michael Watson (Sanofi Pasteur) Chair of IFPMA Biologicals
More informationVaccines: Heroes or Villains?
Vaccines: Heroes or Villains? (Hint: It s the first one) James W. Jarvis, MD, FAAFP Senior Vice President/Senior Physician Executive Northern Light Eastern Maine Medical Center 1 Vaccinations: A brief
More informationCurrent needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution
Current needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution by DR.SURESH S. JADHAV Executive Director Serum Institute of India Ltd/Pune & President
More informationThe administration of covered immunizations and vaccines also is covered.
Covered Benefit: Vaccines & Immunization Definitions: CMP Published: Yes No CMP Link: CPG Link: Pediatric, Adolescent and Adult Routine Preventative Services Immunizations and vaccinations for treatment
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationAppendix An Assessment Tool to Determine the Validity of Vaccine Doses
Appendix 4.4 - An Assessment Tool to Determine the Validity of Vaccine Doses Note: Refer to the Canadian Immunization Guide and New Brunswick (NB) immunization program directives for recommendations for
More informationNew Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines
New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines Antigens Vaccine Approved Age Daptacel Diphtheria, Tetanus, and acellular Pertussis (DTaP)
More informationVaccine. Specific defenses Immunity. natural. acquired. Live vaccines. Killed Inactivated vaccines. Cellular fraction vaccines
Introduction Vaccine has been a importance medical breakthrough in preventing morbidity and mortality from infectious diseases worldwide. Vaccination has managed to eradicate the deadly and mutilating
More informationArmed Services Blood Program Immunization List
Immunization List NOTICE: The Department of Defense (DoD) assumes no risk for the use of this information by non-dod personnel, blood programs, or individual medical institutions. The use of this information
More informationNational Vaccine Plan: From Strategy to Implementation
National Vaccine Plan: From Strategy to Implementation July 26, 2011 Sarah Landry Senior Advisor, National Vaccine Program Office Office of the Assistant Secretary for Health Department of Health and Human
More informationVaccine Development in the Developing World; past, present and future: SEAR Perspective
Speech by Dr Samlee Plianbangchang Regional Director, WHO South-East Asia Vaccine Development in the Developing World; past, present and future: SEAR Perspective 15 June 2010 Bangkok, Thailand Vaccine
More informationGlobal Vaccine Market Features and Trends
Global Vaccine Market Features and Trends Miloud Kaddar Senior Adviser, Health Economist 1 WHO, IVB, Geneva GLOBAL VACCINE MARKET MAIN FEATURES OF THE VACCINE MARKET? NEW TRENDS SINCE 2000? IMPLICATIONS?
More informationObjectives. Immunity. Childhood Immunization Risk of Non-Vaccinated Children 12/22/2015
Childhood Immunization Risk of Non-Vaccinated Children Bertha P. Rojas, Pharm.D. PGY-1 Pharmacy Resident South Miami Hospital Objectives Understand the definition of herd immunity Identify vaccine-preventable
More informationCURRENT DEVELOPMENT IN PEDIATRIC VACCINATION
Univ.-Prof. Dr. med. Heinz-J. SCHMITT Senior Medical Director, Pfizer Vaccines Europe Thessaloniki, February 20th, 2018 CURRENT DEVELOPMENT IN PEDIATRIC VACCINATION Selected Case Fatality Rates Germany,
More informationVaccines: Poised To Deliver Significant Growth in Emerging Markets
Vaccines: Poised To Deliver Significant Growth in Emerging Markets 4 th DVFA Symposium Life Science Pierre Morgon Vice-President, Franchise & Global Marketing Operations, Sanofi Pasteur Frankfurt, May
More informationPractical Applications of Immunology. Chapter 18
Practical Applications of Immunology Chapter 18 I. Vaccines A. Definition A suspension of organisms or fractions of organisms that is used to induce immunity (immunologic memory). The mechanism of memory
More informationBenefit Interpretation
Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents
More informationKeynote Address: The Challenge of Achieving Universal Access to Vaccines
Keynote Address: The Challenge of Achieving Universal Access to Vaccines & AMF Seth Berkley M.D, CEO www.gavi.org 1 Vaccine landscape The world before vaccines Examples of major disease outbreaks Yellow
More informationCoverage of Vaccines Medicaid and Child Health Plus Members
Coverage of Vaccines Medicaid and Child Health Plus Members For children between the ages 0-18, routine recommended vaccinations are covered through Vaccines for Children program [VFC]. Fidelis Care will
More informationBirth 6 wk 10 wk 14 wk 18 wk 6 mo 9 mo 12 mo 15 mo 18 mo mo 2-3 Yr 4-6 Yr 7-10Yr Yr 13-18Yr
Vaccine BCG Age Birth 6 wk 10 wk 14 wk 18 wk 6 mo 9 mo 12 mo 15 mo 18 mo 19-23 mo 2-3 Yr 4-6 Yr 7-10Yr 11-12 Yr 13-18Yr BCG Hep B Hep B1 Hep B2 Hep B3 Polio OPV 0 IPV1 IPV2 IPV3 OPV1 OPV2 IPV B1 OPV3 DTP
More informationIntellectual Property Rights & Vaccines in Developing Countries
Intellectual Property Rights & Vaccines in Developing Countries by Dr. S.S.Jadhav President DCVMN Developing Country Vaccine Manufacturers Network DCVMN Formed in November 2000. 7 members steering committee.
More informationThe administration of covered immunizations and vaccines also is covered.
Covered Benefit: Immunization & Vaccines Definitions: CMP Published: Yes No CMP Link: CPG Link: Pediatric, Adolescent and Adult Routine Preventative Services Immunizations and vaccinations for treatment
More informationAchievements in Public Health, Impact of Vaccines Universal... Children -- United States,
1 of 6 2/10/2005 7:40 PM Weekly April 02, 1999 / 48(12);243-248 Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended for Children -- United States, 1990-1998 At the beginning
More informationFrom development to delivery: Decision-making for the introduction of a new vaccine
From development to delivery: Decision-making for the introduction of a new vaccine Prince Mahidol Award Conference Bangkok, Thailand 1-2 February 2007 Dr. J.M. Okwo-Bele Department of Immunization, Vaccines
More informationThe Scientific Relevance of the ATT Today and from a historical Perspective
www.pei.de The Scientific Relevance of the ATT Today and from a historical Perspective Dr. Klaus Cussler EPAA International Workshop Towards global harmonization of 3Rs in biologicals 15-16 September 2015
More informationHow does the body defend itself?
Prevention of Infection 2 Immunisation 3 rd BDS B. Martin Major World Causes Of Death COUNTRIES Developing Developed Total x10-6 Population 5400 (80%) 1200 (20%) 6600 CAUSE OF DEATH % % % Infectious diseases
More informationVaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines
Vaccine Innovation: Challenges and Opportunities to Protect Health Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines Protecting Health with Vaccines HEALTH IMPROVEMENT Population Impact Guidelines
More information1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector
1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share
More informationVaccines, Not Just for Babies
Vaccines, Not Just for Babies Meg Fisher, MD Medical Director Disclosures I have no relevant financial relationships with the manufacturers of any commercial products or commercial services discussed in
More informationV3P: Region Fact Sheet
V3P: Region Fact Sheet Highlights The 1 region market is 15% of the global market in volume and 63% in value. The regional vaccine procurement habits are different from the rest of the world in several
More informationV3P: Region Fact Sheet
V3P: Region Fact Sheet Highlights The 1 region market is 6% of the world market in volume and 6% in value. The regional vaccine procurement habits are different from the rest of the world in several ways,
More informationFIMDP 2013 DEPT OF COMMUNITY MEDICINE SRM MEDICAL COLLEGE,SRM UNIVERSITY & UNSW AUSTRALIA 9 TH & 10 TH JAN 2013
FIMDP 2013 DEPT OF COMMUNITY MEDICINE SRM MEDICAL COLLEGE,SRM UNIVERSITY & UNSW AUSTRALIA 9 TH & 10 TH JAN 2013 Immunization Dr A Prema Prof. & HOD, Dept of Pediatrics SRM Medical College Beginning of
More informationManaging cost considerations and access to technology for cost effective vaccine manufacture in developing countries.
Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities
More informationVaccines on the Global Scale
Vaccines on the Global Scale Learning from the past and aiming at the future Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health,
More informationEssential Vaccinations for HIV-Positive Adults and Adolescents
Essential Vaccinations for HIV-Positive Adults and Adolescents Janak A. Patel, MD Professor & Director, Pediatric Infectious Diseases Director, Maternal-Child Program University of Texas Medical Branch
More informationVaccinology Overview. Complexity of the Vaccine Approval Process Including Lessons Learned
Vaccinology Overview Complexity of the Vaccine Approval Process Including Lessons Learned Larry K. Pickering, MD, FAAP, FIDSA, FPIDS August 18, 2018 Faculty Disclosure Information In the past 12 months,
More informationAKE WITH Y KEEP AND T
VACCINATION RECORD Vaccination, the best protection This booklet is an important document. It is the only record of all the vaccines you have received. You will need it all your life, so keep it in a safe
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationCyprus Experience. Dr. Elena Papamichael Ministry of Health
Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey
More informationVaccination: lost opportunities
Vaccination: lost opportunities José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. - Formerly at the World Health Organization
More information7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids
7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids Contents Introduction Nunavut Recommended Childhood Immunization Schedule Nunavut Routine Adult Immunization Schedule Nunavut Immunization
More information